CAR T-Cell Therapy in R/R MM: Treatment Selection, Safety, and Future Perspectives

Opinion
Video

Myeloma specialists have a comprehensive discussion on CAR T-cell therapy, highlighting treatment selection considerations, adverse event management strategies, unmet needs, and ongoing research.

Video content above is prompted by the following questions:

  • Can you describe the ideal patient to receive cilta-cel vs ide-cel?
    • In which patient populations would you not choose to give cilta-cel? Ide-cel?
    • What is the role of patient preferences and shared decision-making when choosing between cilta-cel and ide-cel?

  • How does the safety profile factor into your treatment choice?
    • What are the some commonly observed toxicities with CAR T-cell therapy?
    • What are some strategies used to manage adverse events?

  • What are some challenges or barriers seen with CAR T-cell therapy?
    • What are the logistical challenges associated with CAR T-cell therapy and what are the potential solutions?

  • What is the future of CAR T-cell therapy in relapsed/refractory multiple myeloma (R/R MM)?
    • Please highlight any other trials of note investigating the use of cilta-cel or ide-cel for R/R MM.
    • What other targets or dual targets are being investigated? (GPRC5D, CD19, BCMA, etc)
Recent Videos
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
Related Content